Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company is initiating a Phase 3 clinical study titled A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight. The study aims to evaluate the effectiveness and safety of Orforglipron in treating stress urinary incontinence (SUI) in overweight or obese women, a condition characterized by involuntary urine leakage during physical activities.
Intervention/Treatment: The study tests Orforglipron, an oral medication, against a placebo. Orforglipron is intended to manage symptoms of SUI in the target demographic.
Study Design: This interventional study is randomized and follows a parallel assignment model. It employs a double-blind approach, meaning both participants and investigators are unaware of who receives the actual drug versus the placebo. The primary aim is treatment-focused.
Study Timeline: The study is not yet recruiting, with an initial submission date of September 24, 2025, and the latest update on October 8, 2025. These dates are crucial as they mark the study’s progression and readiness to begin participant enrollment.
Market Implications: The initiation of this study could influence Eli Lilly’s stock performance positively, as successful results may lead to a new treatment option for SUI, a condition with significant unmet needs. Investors should monitor this development, especially in the context of competitors focusing on similar therapeutic areas.
The study is ongoing, with further details available on the ClinicalTrials portal.